A D Elias

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
    A D Elias
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 8:198-205. 2002
  2. ncbi request reprint A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer
    A D Elias
    Harvard Medical School, and Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Bone Marrow Transplant 27:269-78. 2001
  3. ncbi request reprint A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies
    A D Elias
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Bone Marrow Transplant 28:447-54. 2001
  4. ncbi request reprint Status of high-dose chemotherapy for breast cancer: a review
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Biol Blood Marrow Transplant 6:476-95. 2000
  5. doi request reprint Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
  6. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
  7. ncbi request reprint Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
    Bhuvaneswari Ramaswamy
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA
    Clin Cancer Res 12:3124-9. 2006
  8. ncbi request reprint Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome
    Anthony D Elias
    Department of Medicine, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 8:326-33. 2002
  9. doi request reprint Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1810-6. 2008
  10. ncbi request reprint Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:4337-43. 2002

Research Grants

  1. UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
    Anthony Elias; Fiscal Year: 2006
  2. UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
    Anthony Elias; Fiscal Year: 2007
  3. UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
    Anthony Elias; Fiscal Year: 2007

Detail Information

Publications11

  1. ncbi request reprint The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
    A D Elias
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 8:198-205. 2002
    ..Although selection biases may have in part contributed to this effect, a randomized comparison of standard therapy versus short induction/double transplantation is warranted...
  2. ncbi request reprint A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer
    A D Elias
    Harvard Medical School, and Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Bone Marrow Transplant 27:269-78. 2001
    ..Whilst selection biases may in part contribute to this effect, a much larger phase II double transplant trial is warranted in preparation for a potential randomized comparison of standard therapy vs single vs double transplant...
  3. ncbi request reprint A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies
    A D Elias
    Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Bone Marrow Transplant 28:447-54. 2001
    ..Whilst selection biases may in part contribute to favorable EFS and OS, a randomized comparison of standard therapy vs double transplant in both metastatic and locally advanced breast cancer is warranted...
  4. ncbi request reprint Status of high-dose chemotherapy for breast cancer: a review
    Y Nieto
    University of Colorado Bone Marrow Transplant Program, Denver 80262, USA
    Biol Blood Marrow Transplant 6:476-95. 2000
    ..This may come through incorporating more active drugs into HDCT regimens and combining HDCT with novel strategies aimed at eradication of posttransplantation minimal residual disease...
  5. doi request reprint Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
    ..PERCHE closed with inadequate accrual; TEXT accrued rapidly...
  6. ncbi request reprint Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623
    Halle C F Moore
    Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 25:1677-82. 2007
    ....
  7. ncbi request reprint Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients
    Bhuvaneswari Ramaswamy
    Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA
    Clin Cancer Res 12:3124-9. 2006
    ..To evaluate the safety and efficacy of bevacizumab and weekly docetaxel as first- or second-line therapy in patients with metastatic breast cancer (MBC)...
  8. ncbi request reprint Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome
    Anthony D Elias
    Department of Medicine, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 8:326-33. 2002
    ..Conversely, 3 of the 7 patients with EPSC remain relapse-free (range, 1-96 months), warranting further phase II evaluation of this approach in this population...
  9. doi request reprint Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
    Harold J Burstein
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 26:1810-6. 2008
    ..This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC)...
  10. ncbi request reprint Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome
    Paul G Richardson
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 100:4337-43. 2002
    ..Certain features associated with successful outcome may correlate with DF-related treatment effects, and prospective evaluation of DF therapy for severe VOD should allow better definition of predictors of response or failure...
  11. ncbi request reprint Autologous stem cell transplantation for small cell lung cancer
    J Douglas Rizzo
    Statistical Center, Health Policy Institute, Medical College of Wisconsin, Milwaukee 53226, USA
    Biol Blood Marrow Transplant 8:273-80. 2002
    ..Transplantation for patients with extensive disease does not appear to produce substantial benefit...

Research Grants5

  1. UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
    Anthony Elias; Fiscal Year: 2006
    ..We are proud of our contributions to the Southwest Oncology Group and are committed to its mission. We expect our Southwest Oncology Group activities to increase in the next grant cycle. ..
  2. UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
    Anthony Elias; Fiscal Year: 2007
    ..Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado. ..
  3. UNIVERSITY OF COLORADO SOUTHWEST ONCOLOGY GROUP
    Anthony Elias; Fiscal Year: 2007
    ..Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado. ..